US 12,005,081 B2
Chimeric receptors and methods of use thereof
Brian Scott Garrison, Saratoga, CA (US); Jennifer Chien, Fremont, CA (US); Kathryn Armstrong Loving, Berkeley, CA (US); Russell Morrison Gordley, San Francisco, CA (US); and Michelle Elizabeth Hung, South San Francisco, CA (US)
Assigned to Senti Biosciences, Inc., South San Francisco, CA (US)
Filed by Senti Biosciences, Inc., South San Francisco, CA (US)
Filed on Jun. 3, 2021, as Appl. No. 17/338,528.
Application 17/338,528 is a continuation of application No. PCT/US2020/030640, filed on Apr. 30, 2020.
Claims priority of provisional application 62/893,106, filed on Aug. 28, 2019.
Claims priority of provisional application 62/854,151, filed on May 29, 2019.
Claims priority of provisional application 62/841,128, filed on Apr. 30, 2019.
Prior Publication US 2021/0299177 A1, Sep. 30, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); A61K 38/00 (2006.01)
CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); A61K 38/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 28 Claims
 
1. A method of treating a subject having acute myeloid leukemia (AML), wherein the method comprises delivering to the subject an autologous or an allogeneic T cell or Natural Killer (NK) cell comprising:
(a) an anti-FLT3 chimeric antigen receptor (CAR) comprising a FLT3-binding domain and an anti-CD33 CAR comprising a CD33-binding domain, or a bivalent CAR comprising a FLT3-binding domain and a CD33-binding domain,
wherein the FLT3-binding domain comprises a heavy chain variable domain (VH) comprising a CDR-H1 sequence comprising the amino acid sequence of SEQ ID NO: 81, a CDR-H2 sequence comprising the amino acid sequence of SEQ ID NO: 82, and a CDR-H3 sequence comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable domain (VL) comprising a CDR-L1 sequence comprising the amino acid sequence of SEQ ID NO: 84, a CDR-L2 sequence comprising the amino acid sequence of SEQ ID NO: 85, and a CDR-L3 sequence comprising the amino acid sequence of SEQ ID NO: 86, and
wherein the CD33-binding domain comprises VH comprising a CDR-H1 sequence comprising the amino acid sequence of SEQ ID NO: 123, a CDR-H2 sequence comprising the amino acid sequence of SEQ ID NO: 124, and a CDR-H3 sequence comprising the amino acid sequence of SEQ ID NO: 125 and a VL comprising a CDR-L1 sequence comprising the amino acid sequence of SEQ ID NO: 126, a CDR-L2 sequence comprising the amino acid sequence of SEQ ID NO: 127, and a CDR-L3 sequence comprising the amino acid sequence of SEQ ID NO: 128; and
(b) an inhibitory chimeric receptor comprising an extracellular antigen-binding domain that binds to EMCN.